Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer

被引：8

作者：

Choe, Jooae ^{[1
,2
]}

Braschi-Amirfarzan, Marta ^{[3
,4
]}

Tirumani, Sree Harsha ^{[4
]}

Shinagare, Atul B. ^{[3
,4
]}

Kim, Kyung Won ^{[1
,2
]}

Ramaiya, Nikhil H. ^{[3
,4
]}

Krajewski, Katherine M. ^{[3
,4
]}

机构：

[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, 86 Asanbyeongwon Gil, Seoul 138736, South Korea

[2] Univ Ulsan, Coll Med, Asan Med Ctr, Res Inst Radiol, 86 Asanbyeongwon Gil, Seoul 138736, South Korea

[3] Harvard Med Sch, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA

[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA

来源：

ABDOMINAL RADIOLOGY | 2017年 / 42卷 / 11期

关键词：

Bladder cancer; Urothelial carcinoma; Diagnosis; Management; Oncologic imaging; COMPUTED-TOMOGRAPHY UROGRAPHY; GEMCITABINE PLUS CISPLATIN; URINARY-BLADDER; UROTHELIAL CARCINOMA; RADICAL CYSTECTOMY; MDCT UROGRAPHY; CT UROGRAPHY; LYMPH-NODES; FOLLOW-UP; RECURRENCE;

D O I：

10.1007/s00261-017-1195-3

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Urothelial bladder cancer is a common malignancy requiring a multidisciplinary approach to treatment. Significant recent advances have been made in terms of the genetic and molecular characterization of bladder cancer subtypes, and novel treatment approaches are being investigated and approved. Given the important role of imaging in the diagnosis, staging, and follow-up of this disease, it is necessary for radiologists to remain up-to-date in terms of nomenclature and standards of care. In this review, recent developments in bladder cancer characterization and treatment will be discussed, with reference to the contributions of imaging in non-muscle-invasive, muscle-invasive, and metastatic settings.

引用

页码：2710 / 2724

页数：15

共 76 条

[1] American Cancer Society, 2016, SIGNS SYMPT BLADD CA
[2] American Cancer Society, KEY STAT BLADD CANC
[3] American College of Radiology, 2014, ACR APPR CRIT
[4] [Anonymous], 2016, WHO classification of tumours of the urinary system and male genital organs
[5] [Anonymous], 2020, NCCN Clinical Practice Guidelines in Oncology: Survivorship
[6] [Anonymous], 2016, Cancer treatment survivorship facts figures 2016-2017
[7] [Anonymous], 2016, ANN ONCOL, DOI [10.1093/annonc/mdw435.25, DOI 10.1093/ANNONC/MDW435.25]
[8] Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging
Barentsz, JO
Berger-Hartog, O
Witjes, JA
Hulsbergen-van der Kaa, C
Oosterhof, GON
VanderLaak, JAWM
Kondacki, H
Ruijs, SHJ
[J]. RADIOLOGY, 1998, 207 (03) : 791 - 797
[9] Bladder cancer:: can imaging change patient management?
Beyersdorff, Dirk
Zhang, Jingbo
Schoeder, Heiko
Bochner, Bernard
Hricak, Hedvig
[J]. CURRENT OPINION IN UROLOGY, 2008, 18 (01) : 98 - 104
[10] Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
Billerey, C
Chopin, D
Aubriot-Lorton, MH
Ricol, D
de Medina, SGD
Van Rhijn, B
Bralet, MP
Lefrere-Belda, MA
Lahaye, JB
Abbou, CC
Bonaventure, J
Zafrani, ES
van der Kwast, T
Thiery, JP
Radvanyi, F
[J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) : 1955 - 1959

← 1 2 3 4 5 6 7 8 →